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1. Now that ERT enables patients with classic infantile Pompe disease to live longer, a 
new phenotype is emerging that differs from that of children and adults with non-
classic Pompe disease. {dit proefschrift) 
2. New features in long-term survivors are facial-muscle weakness and-ptosis, speech 
disorders, dysphagia, impaired motor function, and distal muscle weakness. (dit 
proefschrift) 
3. Although ERT is unlikely to cross the blood-brain barrier in patients with classic 
infantile Pompe disease treated with ERT, glycogen storage seems to have limited 
impact on the function of the CNS during childhood. (dit proefschrift) 
4. Clinical outcome in patients with classic infantile Pompe disease t reated with 
ERT can be improved by dose augmentation, immunomodulation, and neonatal 
screening. (dit proefschrift) 
5. The pathophysiological mechanisms of LSDs should be further elucidated, as they 
might prompt the development of new and ultimately curative therapies. (dit 
proefschrift) 
6. Centralisatie van zorg vraagt extra tijd van de patient maar leidt tot kwalitatief 
betere zorg. 
7. De klinische relevantie moet leidend zijn bij het beoordelen van de effectiviteit van 
een geneesmiddel. 
8. "As to diseases, make a habit of two things: To help, or at least, to do no harm." 
{Hippocrates) 
9. "Nothing's ever for sure. That's the only sure th ing I do know." A beautiful mind. 
10. "They do certainly give very strange, and newfangled, names to diseases." {Plato) 
11. Een dag niet genieten is een dag niet geleefd. (G. van den Berg) 
